Enfusion (NYSE:ENFN) Receives New Coverage from Analysts at Morgan Stanley

Stock analysts at Morgan Stanley started coverage on shares of Enfusion (NYSE:ENFN - Get Free Report) in a research report issued to clients and investors on Friday, StockNewsAPI reports. The firm set an "overweight" rating and a $11.00 price target on the stock. Morgan Stanley's price target points to a potential upside of 21.55% from the company's previous close.

A number of other equities research analysts also recently issued reports on ENFN. JPMorgan Chase & Co. downgraded Enfusion from a "neutral" rating to an "underweight" rating and cut their price target for the company from $11.00 to $9.00 in a research note on Tuesday, January 30th. Bank of America boosted their target price on shares of Enfusion from $8.00 to $9.00 and gave the company an "underperform" rating in a research report on Wednesday, March 13th. Finally, The Goldman Sachs Group downgraded shares of Enfusion from a "neutral" rating to a "sell" rating and decreased their price target for the stock from $9.00 to $8.00 in a research report on Wednesday, February 28th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, Enfusion presently has an average rating of "Hold" and an average price target of $9.33.

Enfusion Stock Performance

Shares of ENFN traded down $0.21 during mid-day trading on Friday, hitting $9.05. 504,031 shares of the company traded hands, compared to its average volume of 294,748. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of 113.14, a P/E/G ratio of 2.85 and a beta of 0.97. The stock has a 50-day moving average price of $9.23 and a two-hundred day moving average price of $9.17. Enfusion has a 1 year low of $7.37 and a 1 year high of $11.56.

Enfusion (NYSE:ENFN - Get Free Report) last announced its earnings results on Thursday, May 9th. The company reported ($0.01) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.05). The company had revenue of $48.05 million for the quarter, compared to analysts' expectations of $47.67 million. Enfusion had a net margin of 3.45% and a return on equity of 10.30%. During the same quarter in the prior year, the firm posted $0.04 earnings per share. On average, analysts forecast that Enfusion will post 0.07 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Enfusion by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 3,653,189 shares of the company's stock worth $33,792,000 after purchasing an additional 51,670 shares during the period. Bleakley Financial Group LLC bought a new position in shares of Enfusion in the 1st quarter valued at about $176,000. Susquehanna Fundamental Investments LLC bought a new stake in Enfusion during the first quarter worth approximately $122,000. Swiss National Bank raised its position in Enfusion by 20.0% during the first quarter. Swiss National Bank now owns 69,700 shares of the company's stock valued at $645,000 after purchasing an additional 11,600 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Enfusion in the 1st quarter valued at approximately $44,000. Institutional investors own 81.05% of the company's stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.